Literature DB >> 22841678

Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas.

Mark W Lingen1, Weihong Xiao, Alessandra Schmitt, Bo Jiang, Robert Pickard, Paul Kreinbrink, Bayardo Perez-Ordonez, Richard C Jordan, Maura L Gillison.   

Abstract

BACKGROUND: Human papillomavirus (HPV) is a cause of oropharyngeal cancer, but a role for HPV in the etiology of oral cavity squamous cell carcinomas (OCSCC) remains uncertain.
METHODS: We sought to estimate the etiologic fraction for HPV among consecutive, incident OCSCC diagnosed from 2005 to 2011 at four North American hospitals. DNA and RNA purified from paraffin-embedded tumors were considered evaluable if positive for DNA and mRNA control genes by quantitative PCR. Fifteen high-risk (HR) HPV types were detected in tumors by consensus PCR followed by type-specific HR-HPV E6/7 oncogene expression by quantitative reverse-transcriptase PCR. P16 expression was evaluated by immunohistochemistry (IHC). A study of 400 cases allowed for precision to estimate an etiologic fraction of as low as 0% (97.5% confidence interval, 0-0.92%).
RESULTS: Of 409 evaluable OCSCC, 24 (5.9%, 95%CI 3.6-8.2) were HR-HPV E6/7 expression positive; 3.7% (95%CI 1.8-5.5) for HPV16 and 2.2% (95%CI 0.8-3.6) for other HR-HPV types. HPV-positive tumors arose from throughout the oral cavity (floor of mouth [n=9], anterior tongue [6], alveolar process [4], hard palate [3], gingiva [1] and lip [1]) and were significantly associated with male gender, small tumor stage, poor tumor differentiation, and basaloid histopathology. P16 IHC had very good-to-excellent sensitivity (79.2%, 95%CI 57.9-92.9), specificity (93.0%, 95%CI 90.0-95.3), and negative-predictive value (98.6%, 95%CI 96.8-99.6), but poor positive-predictive value (41.3%, 95%CI 27.0-56.8) for HR-HPV E6/7 expression in OCSCC.
CONCLUSION: The etiologic fraction for HR-HPV in OCSCC was 5.9%. p16 IHC had poor positive predictive value for detection of HPV in these cancers.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841678     DOI: 10.1016/j.oraloncology.2012.07.002

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  108 in total

1.  Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice.

Authors:  Haïtham Mirghani; Odile Casiraghi; Furrat Amen; Mingxiao He; Xiao-Jun Ma; Patrick Saulnier; Ludovic Lacroix; Françoise Drusch; Aïcha Ben Lakdhar; Jean Lacau Saint Guily; Cécile Badoual; Jean Yves Scoazec; Philippe Vielh
Journal:  Mod Pathol       Date:  2015-09-25       Impact factor: 7.842

Review 2.  Discussing the diagnosis of HPV-OSCC: common questions and answers.

Authors:  Carole Fakhry; Gypsyamber D'Souza
Journal:  Oral Oncol       Date:  2013-07-19       Impact factor: 5.337

3.  p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.

Authors:  Christine H Chung; Qiang Zhang; Christina S Kong; Jonathan Harris; Elana J Fertig; Paul M Harari; Dian Wang; Kevin P Redmond; George Shenouda; Andy Trotti; David Raben; Maura L Gillison; Richard C Jordan; Quynh-Thu Le
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 4.  HPV and cancer of the oral cavity.

Authors:  Christian U Hübbers; Baki Akgül
Journal:  Virulence       Date:  2015       Impact factor: 5.882

5.  SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.

Authors:  Hiroyuki Ozawa; Ruchira S Ranaweera; Evgeny Izumchenko; Eugene Makarev; Alex Zhavoronkov; Elana J Fertig; Jason D Howard; Ana Markovic; Atul Bedi; Rajani Ravi; Jimena Perez; Quynh-Thu Le; Christina S Kong; Richard C Jordan; Hao Wang; Hyunseok Kang; Harry Quon; David Sidransky; Christine H Chung
Journal:  Clin Cancer Res       Date:  2017-05-18       Impact factor: 12.531

6.  Guidelines for the Surgical Management of Oral Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Young-Hoon Joo; Jae-Keun Cho; Bon Seok Koo; Minsu Kwon; Seong Keun Kwon; Soon Young Kwon; Min-Su Kim; Jeong Kyu Kim; Heejin Kim; Innchul Nam; Jong-Lyel Roh; Young Min Park; Il-Seok Park; Jung Je Park; Sung-Chan Shin; Soon-Hyun Ahn; Seongjun Won; Chang Hwan Ryu; Tae Mi Yoon; Giljoon Lee; Doh Young Lee; Myung-Chul Lee; Joon Kyoo Lee; Jin Choon Lee; Jae-Yol Lim; Jae Won Chang; Jeon Yeob Jang; Man Ki Chung; Yuh-Seok Jung; Jae-Gu Cho; Yoon Seok Choi; Jeong-Seok Choi; Guk Haeng Lee; Phil-Sang Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-02-02       Impact factor: 3.372

7.  Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke.

Authors:  Ryan Li; Daniel L Faden; Carole Fakhry; Chaz Langelier; Yuchen Jiao; Yuxuan Wang; Matthew D Wilkerson; Chandra Sekhar Pedamallu; Matthew Old; James Lang; Myriam Loyo; Sun Mi Ahn; Marietta Tan; Zhen Gooi; Jason Chan; Jeremy Richmon; Laura D Wood; Ralph H Hruban; Justin Bishop; William H Westra; Christine H Chung; Joseph Califano; Christine G Gourin; Chetan Bettegowda; Matthew Meyerson; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Joseph L DeRisi; Wayne M Koch; Nishant Agrawal
Journal:  Head Neck       Date:  2014-08-23       Impact factor: 3.147

Review 8.  PPARγ in head and neck cancer prevention.

Authors:  Mauricio Burotto; Eva Szabo
Journal:  Oral Oncol       Date:  2014-01-13       Impact factor: 5.337

9.  Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas.

Authors:  William H Westra
Journal:  Oral Oncol       Date:  2014-06-02       Impact factor: 5.337

10.  Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes.

Authors:  Blanche P Alter; Neelam Giri; Yuanji Pan; Sharon A Savage; Ligia A Pinto
Journal:  Vaccine       Date:  2013-12-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.